Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) saw its stock touch a 52-week low of $518.68 as the biotech firm contends with heightened market volatility and shifting investor sentiment. The stock ...

Regeneron Pharmaceuticals Inc. closed 55.21% below its 52-week high of $1,211.20, which the company reached on August 27th.

Regeneron (REGN) stock price corrected sharply in recent months. ... in which I argued, based on technical analysis, market sentiment analysis, and catalysts, ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet ...

Data & APIs. Events. Premarket ...

A few months back in December 2020, we discussed why Regeneron stock looks undervalued. The stock since then has had a volatile ride with gains of 7% between early December 2020 and late January ...

Over the past five years, Regeneron Pharmaceuticals' total shareholder return reached 46.55%, showcasing its resilience amidst a challenging market. This period witnessed several pivotal developments.

Regeneron Pharmaceuticals’ Debt total was $2.7 Billion at the conclusion of the most recent quarter, while its market capitalization is $52 Billion (as of 5/30/2025).

Regeneron: Market Overlooks A Resilient Franchise And Robust Free Cash Flow. Apr. 06, 2025 2:36 AM ET Regeneron Pharmaceuticals, Inc. (REGN) Stock SNY, REGN 35 Comments 1 Like. Stephen Ayers.

Regeneron Pharmaceuticals has delivered market-beating results for shareholders over the prior 10 years. With competition heating up, however, the biotech may be entering a period of slowing growth.

Dupixent sales were $3.7 billion in the quarter, up 15% year over year, and Regeneron’s collaboration revenue from Sanofi was 1.2 billion, or a 22% year-on-year increase.